Sales of $17.4 Billion decreased 4.1% Versus 2014 First Quarter;
First-Quarter EPS was $1.53
Adjusted 2015 First-Quarter EPS of $1.56 Decreased 4.3%*
Net earnings and diluted earnings per share for the first quarter of 2015 were
"The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business. Of note is the continued robust growth of the Pharmaceutical business and the solid performance of our Consumer brands," said
The Company updated its adjusted earnings guidance for full-year 2015 to
Worldwide Consumer sales of
Positive contributors to operational results were sales of TYLENOL® and MOTRIN® analgesics, digestive health and international upper-respiratory over-the-counter products;
Worldwide Pharmaceutical sales of
The strong operational sales results were driven by new products and the strength of core products. New products include INVOKANA®/INVOKAMET® (canagliflozin), for the treatment of adults with type 2 diabetes; XARELTO® (rivaroxaban), an oral anticoagulant; IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; and international sales of OLYSIO®(simeprevir), for combination treatment of chronic hepatitis C in adult patients. New product sales growth was negatively impacted by lower sales of OLYSIO® (simeprevir) in the U.S. and lower sales of SOVRIAD® (simeprevir) in
Additional contributors to operational sales growth were STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; CONCERTA®(methylphenidate HCI), for the treatment of attention deficit hyperactivity disorder; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI®/SIMPONI ARIA® (golimumab) and domestic sales of REMICADE® (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.
During the quarter, the
In addition, the acquisition of
Worldwide Medical Devices sales of
Primary contributors to operational growth were sales of Orthopaedic products; electrophysiology products in the Cardiovascular Care business; endocutters in the Surgical Care business; and sales of insulin delivery products in the Diabetes Care business. Sales results in the Vision Care business were negatively impacted by buying patterns and competitive pricing dynamics.
During the quarter, the Company announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of
About
Caring for the world, one person at a time, inspires and unites the people of
* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings and adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
|
|||||||||||
Supplementary Sales Data |
|||||||||||
(Unaudited; Dollars in Millions) |
FIRST QUARTER |
||||||||||
Percent Change |
|||||||||||
2015 |
2014 |
Total |
Operations |
Currency |
|||||||
Sales to customers by |
|||||||||||
segment of business |
|||||||||||
Consumer |
|||||||||||
U.S. |
$ 1,359 |
1,309 |
3.8 |
% |
3.8 |
- |
|||||
International |
2,031 |
2,248 |
(9.7) |
3.1 |
(12.8) |
||||||
3,390 |
3,557 |
(4.7) |
3.4 |
(8.1) |
|||||||
Pharmaceutical |
|||||||||||
U.S. |
4,371 |
3,740 |
16.9 |
16.9 |
- |
||||||
International |
3,355 |
3,758 |
(10.7) |
3.7 |
(14.4) |
||||||
7,726 |
7,498 |
3.0 |
10.2 |
(7.2) |
|||||||
Medical Devices |
|||||||||||
U.S. |
2,962 |
3,155 |
(6.1) |
(6.1) |
- |
||||||
International |
3,296 |
3,905 |
(15.6) |
(3.3) |
(12.3) |
||||||
6,258 |
7,060 |
(11.4) |
(4.6) |
(6.8) |
|||||||
U.S. |
8,692 |
8,204 |
5.9 |
5.9 |
- |
||||||
International |
8,682 |
9,911 |
(12.4) |
0.8 |
(13.2) |
||||||
Worldwide |
$ 17,374 |
18,115 |
(4.1) |
% |
3.1 |
(7.2) |
|||||
|
|||||||||||
Supplementary Sales Data |
|||||||||||
(Unaudited; Dollars in Millions) |
FIRST QUARTER |
||||||||||
Percent Change |
|||||||||||
2015 |
2014 |
Total |
Operations |
Currency |
|||||||
Sales to customers by |
|||||||||||
geographic area |
|||||||||||
U.S. |
$ 8,692 |
8,204 |
5.9 |
% |
5.9 |
- |
|||||
Europe |
4,040 |
4,885 |
(17.3) |
0.3 |
(17.6) |
||||||
Western Hemisphere excluding U.S. |
1,639 |
1,695 |
(3.3) |
9.9 |
(13.2) |
||||||
|
3,003 |
3,331 |
(9.8) |
(3.0) |
(6.8) |
||||||
International |
8,682 |
9,911 |
(12.4) |
0.8 |
(13.2) |
||||||
Worldwide |
$ 17,374 |
18,115 |
(4.1) |
% |
3.1 |
(7.2) |
|||||
|
||||||||||
Condensed Consolidated Statement of Earnings |
||||||||||
(Unaudited; in Millions Except Per Share Figures) |
FIRST QUARTER |
|||||||||
2015 |
2014 |
Percent |
||||||||
Percent |
Percent |
Increase |
||||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
||||||
Sales to customers |
$ 17,374 |
100.0 |
$ 18,115 |
100.0 |
(4.1) |
|||||
Cost of products sold |
5,282 |
30.4 |
5,455 |
30.1 |
(3.2) |
|||||
Selling, marketing and administrative expenses |
4,847 |
27.9 |
5,183 |
28.6 |
(6.5) |
|||||
Research and development expense |
1,899 |
10.9 |
1,831 |
10.1 |
3.7 |
|||||
In-process research and development |
- |
- |
18 |
0.1 |
||||||
Interest (income) expense, net |
119 |
0.7 |
118 |
0.7 |
||||||
Other (income) expense, net |
(348) |
(2.0) |
86 |
0.5 |
||||||
Earnings before provision for taxes on income |
5,575 |
32.1 |
5,424 |
29.9 |
2.8 |
|||||
Provision for taxes on income |
1,255 |
7.2 |
697 |
3.8 |
80.1 |
|||||
Net earnings |
4,320 |
24.9 |
4,727 |
26.1 |
(8.6) |
|||||
Net earnings per share (Diluted) |
$ 1.53 |
$ 1.64 |
(6.7) |
|||||||
Average shares outstanding (Diluted) |
2,826.0 |
2,874.7 |
||||||||
Effective tax rate |
22.5 |
% |
12.9 |
% |
||||||
Adjusted earnings before provision for taxes and net earnings (1) |
||||||||||
Earnings before provision for taxes on income |
$ 5,630 |
32.4 |
$ 5,928 |
32.7 |
(5.0) |
|||||
Net earnings |
$ 4,418 |
25.4 |
$ 4,693 |
25.9 |
(5.9) |
|||||
Net earnings per share (Diluted) |
$ 1.56 |
$ 1.63 |
(4.3) |
|||||||
Effective tax rate |
21.5 |
% |
20.8 |
% |
||||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
||||||||||
|
||||||||||
Reconciliation of Non-GAAP Financial Measures |
||||||||||
First Quarter |
% Incr. / |
|||||||||
(Dollars in Millions Except Per Share Data) |
2015 |
2014 |
(Decr.) |
|||||||
Earnings before provision for taxes on income - as reported |
$ 5,575 |
5,424 |
2.8 |
% |
||||||
Intangible asset amortization expense |
312 |
368 |
||||||||
Litigation gain, net |
(402) |
- |
||||||||
DePuy ASRTMHip program |
139 |
- |
||||||||
Synthes integration costs |
32 |
118 |
||||||||
|
(26) |
- |
||||||||
In-process research and development |
- |
18 |
||||||||
Earnings before provision for taxes on income - as adjusted |
$ 5,630 |
5,928 |
(5.0) |
% |
||||||
Net Earnings - as reported |
$ 4,320 |
4,727 |
(8.6) |
% |
||||||
Intangible asset amortization expense |
226 |
267 |
||||||||
Litigation gain, net |
(253) |
- |
||||||||
DePuy ASRTMHip program |
122 |
- |
||||||||
Synthes integration costs |
25 |
84 |
||||||||
|
(22) |
- |
||||||||
In-process research and development |
- |
13 |
||||||||
Tax benefit associated with |
- |
(398) |
||||||||
Net Earnings - as adjusted |
$ 4,418 |
4,693 |
(5.9) |
% |
||||||
Diluted Net Earnings per share - as reported |
$ 1.53 |
1.64 |
(6.7) |
% |
||||||
Intangible asset amortization expense |
0.08 |
0.09 |
||||||||
Litigation gain, net |
(0.09) |
- |
||||||||
DePuy ASRTMHip program |
0.04 |
- |
||||||||
Synthes integration costs |
0.01 |
0.03 |
||||||||
|
(0.01) |
- |
||||||||
In-process research and development |
- |
0.01 |
||||||||
Tax benefit associated with |
- |
(0.14) |
||||||||
Diluted Net Earnings per share - as adjusted |
$ 1.56 |
1.63 |
(4.3) |
% |
||||||
|
|||||||||
Reconciliation of Non-GAAP Financial Measure |
|||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
|||||||||
FIRST QUARTER 2015 ACTUAL vs. 2014 ACTUAL |
|||||||||
Segments |
|||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
||||||
Operational % (1) |
|||||||||
WW As Reported: |
3.4% |
10.2% |
(4.6)% |
3.1% |
|||||
U.S. |
3.8% |
16.9% |
(6.1)% |
5.9% |
|||||
International |
3.1% |
3.7% |
(3.3)% |
0.8% |
|||||
Women's Health |
|||||||||
K-Y ® |
0.7 |
0.1 |
|||||||
U.S. |
1.3 |
0.2 |
|||||||
International |
0.4 |
0.1 |
|||||||
Wound Care / Other |
|||||||||
BENECOL ® |
0.7 |
0.1 |
|||||||
U.S. |
0.0 |
0.0 |
|||||||
International |
1.2 |
0.3 |
|||||||
Diagnostics |
|||||||||
Ortho-Clinical Diagnostics |
5.9 |
2.4 |
|||||||
U.S. |
7.2 |
3.0 |
|||||||
International |
4.8 |
1.9 |
|||||||
All Other Acquisitions and Divestitures |
(0.1) |
0.0 |
|||||||
U.S. |
0.0 |
0.0 |
|||||||
International |
(0.2) |
(0.1) |
|||||||
WW Ops excluding Acquisitions and Divestitures |
4.7% |
10.2% |
1.3% |
5.7% |
|||||
U.S. |
5.1% |
16.9% |
1.1% |
9.1% |
|||||
International |
4.5% |
3.7% |
1.5% |
3.0% |
|||||
(1)Operational growth excludes the effect of translational currency |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||
FIRST QUARTER |
||||||||
% Change |
||||||||
2015 |
2014 |
Reported |
Operational (1) |
Currency |
||||
CONSUMER SEGMENT (2) |
||||||||
BABY |
||||||||
US |
$ 111 |
102 |
8.8% |
8.8% |
- |
|||
Intl |
400 |
443 |
-9.7% |
-0.9% |
-8.8% |
|||
WW |
511 |
545 |
-6.2% |
1.0% |
-7.2% |
|||
ORAL |
||||||||
US |
158 |
160 |
-1.3% |
-1.3% |
- |
|||
Intl |
245 |
251 |
-2.4% |
8.8% |
-11.2% |
|||
WW |
403 |
411 |
-1.9% |
5.0% |
-6.9% |
|||
OTC |
||||||||
US |
405 |
366 |
10.7% |
10.7% |
- |
|||
Intl |
588 |
645 |
-8.8% |
9.1% |
-17.9% |
|||
WW |
993 |
1,011 |
-1.8% |
9.6% |
-11.4% |
|||
SKIN |
||||||||
US |
492 |
457 |
7.7% |
7.7% |
- |
|||
Intl |
411 |
457 |
-10.1% |
1.5% |
-11.6% |
|||
WW |
903 |
914 |
-1.2% |
4.6% |
-5.8% |
|||
WOMEN'S HEALTH |
||||||||
US |
6 |
24 |
-75.0% |
-75.0% |
- |
|||
Intl |
281 |
303 |
-7.3% |
5.5% |
-12.8% |
|||
WW |
287 |
327 |
-12.2% |
-0.4% |
-11.8% |
|||
WOUND |
||||||||
US |
187 |
200 |
-6.5% |
-6.5% |
- |
|||
Intl |
106 |
149 |
-28.9% |
-19.7% |
-9.2% |
|||
WW |
293 |
349 |
-16.0% |
-12.1% |
-3.9% |
|||
TOTAL CONSUMER |
||||||||
US |
1,359 |
1,309 |
3.8% |
3.8% |
- |
|||
Intl |
2,031 |
2,248 |
-9.7% |
3.1% |
-12.8% |
|||
WW |
$ 3,390 |
3,557 |
-4.7% |
3.4% |
-8.1% |
|||
See footnotes at end of schedule |
||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||
FIRST QUARTER |
||||||||
% Change |
||||||||
2015 |
2014 |
Reported |
Operational (1) |
Currency |
||||
PHARMACEUTICAL SEGMENT (2) (3) |
||||||||
IMMUNOLOGY |
||||||||
US |
$ 1,755 |
1,547 |
13.4% |
13.4% |
- |
|||
Intl |
708 |
796 |
-11.1% |
3.1% |
-14.2% |
|||
WW |
2,463 |
2,343 |
5.1% |
9.9% |
-4.8% |
|||
REMICADE |
||||||||
US |
1,055 |
997 |
5.8% |
5.8% |
- |
|||
US Exports (4) |
181 |
167 |
8.4% |
8.4% |
- |
|||
Intl |
364 |
446 |
-18.4% |
-6.2% |
-12.2% |
|||
WW |
1,600 |
1,610 |
-0.6% |
2.8% |
-3.4% |
|||
SIMPONI / SIMPONI ARIA |
||||||||
US |
155 |
104 |
49.0% |
49.0% |
- |
|||
Intl |
145 |
155 |
-6.5% |
9.7% |
-16.2% |
|||
WW |
300 |
259 |
15.8% |
25.5% |
-9.7% |
|||
STELARA |
||||||||
US |
364 |
279 |
30.5% |
30.5% |
- |
|||
Intl |
185 |
177 |
4.5% |
22.5% |
-18.0% |
|||
WW |
549 |
456 |
20.4% |
27.4% |
-7.0% |
|||
OTHER IMMUNOLOGY |
||||||||
US |
- |
- |
- |
- |
- |
|||
Intl |
14 |
18 |
-22.2% |
-13.7% |
-8.5% |
|||
WW |
14 |
18 |
-22.2% |
-13.7% |
-8.5% |
|||
INFECTIOUS DISEASES |
||||||||
US |
412 |
561 |
-26.6% |
-26.6% |
- |
|||
Intl |
563 |
639 |
-11.9% |
4.2% |
-16.1% |
|||
WW |
975 |
1,200 |
-18.8% |
-10.2% |
-8.6% |
|||
EDURANT |
||||||||
US |
9 |
5 |
80.0% |
80.0% |
- |
|||
Intl |
82 |
76 |
7.9% |
30.6% |
-22.7% |
|||
WW |
91 |
81 |
12.3% |
33.6% |
-21.3% |
|||
OLYSIO / SOVRIAD |
||||||||
US |
98 |
291 |
-66.3% |
-66.3% |
- |
|||
Intl |
136 |
63 |
* |
* |
** |
|||
WW |
234 |
354 |
-33.9% |
-26.2% |
-7.7% |
|||
PREZISTA / PREZCOBIX |
||||||||
US |
234 |
214 |
9.3% |
9.3% |
- |
|||
Intl |
193 |
231 |
-16.5% |
-1.6% |
-14.9% |
|||
WW |
427 |
445 |
-4.0% |
3.7% |
-7.7% |
|||
OTHER INFECTIOUS DISEASES |
||||||||
US |
71 |
51 |
39.2% |
39.2% |
- |
|||
Intl |
152 |
269 |
-43.5% |
-34.5% |
-9.0% |
|||
WW |
223 |
320 |
-30.3% |
-22.8% |
-7.5% |
|||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||
FIRST QUARTER |
||||||||
% Change |
||||||||
2015 |
2014 |
Reported |
Operational (1) |
Currency |
||||
NEUROSCIENCE |
||||||||
US |
750 |
601 |
24.8% |
24.8% |
- |
|||
Intl |
868 |
1,037 |
-16.3% |
-3.2% |
-13.1% |
|||
WW |
1,618 |
1,638 |
-1.2% |
7.1% |
-8.3% |
|||
CONCERTA / METHYLPHENIDATE |
||||||||
US |
126 |
35 |
* |
* |
- |
|||
Intl |
98 |
115 |
-14.8% |
-3.5% |
-11.3% |
|||
WW |
224 |
150 |
49.3% |
58.0% |
-8.7% |
|||
INVEGA |
||||||||
US |
94 |
86 |
9.3% |
9.3% |
- |
|||
Intl |
61 |
79 |
-22.8% |
-8.7% |
-14.1% |
|||
WW |
155 |
165 |
-6.1% |
0.7% |
-6.8% |
|||
INVEGA SUSTENNA / XEPLION |
||||||||
US |
228 |
182 |
25.3% |
25.3% |
- |
|||
Intl |
183 |
191 |
-4.2% |
12.5% |
-16.7% |
|||
WW |
411 |
373 |
10.2% |
18.7% |
-8.5% |
|||
RISPERDAL CONSTA |
||||||||
US |
104 |
106 |
-1.9% |
-1.9% |
- |
|||
Intl |
150 |
204 |
-26.5% |
-13.0% |
-13.5% |
|||
WW |
254 |
310 |
-18.1% |
-9.2% |
-8.9% |
|||
OTHER NEUROSCIENCE |
||||||||
US |
198 |
192 |
3.1% |
3.1% |
- |
|||
Intl |
376 |
448 |
-16.1% |
-4.5% |
-11.6% |
|||
WW |
574 |
640 |
-10.3% |
-2.2% |
-8.1% |
|||
ONCOLOGY |
||||||||
US |
334 |
240 |
39.2% |
39.2% |
- |
|||
Intl |
774 |
782 |
-1.0% |
15.7% |
-16.7% |
|||
WW |
1,108 |
1,022 |
8.4% |
21.2% |
-12.8% |
|||
IMBRUVICA |
||||||||
US |
66 |
6 |
* |
* |
- |
|||
Intl |
50 |
4 |
* |
* |
** |
|||
WW |
116 |
10 |
* |
* |
** |
|||
VELCADE |
||||||||
US |
- |
- |
- |
- |
- |
|||
Intl |
339 |
408 |
-16.9% |
-4.0% |
-12.9% |
|||
WW |
339 |
408 |
-16.9% |
-4.0% |
-12.9% |
|||
ZYTIGA |
||||||||
US |
253 |
229 |
10.5% |
10.5% |
- |
|||
Intl |
303 |
283 |
7.1% |
26.3% |
-19.2% |
|||
WW |
556 |
512 |
8.6% |
19.2% |
-10.6% |
|||
OTHER ONCOLOGY |
||||||||
US |
15 |
5 |
* |
* |
- |
|||
Intl |
82 |
87 |
-5.7% |
10.1% |
-15.8% |
|||
WW |
97 |
92 |
5.4% |
20.3% |
-14.9% |
|||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||
FIRST QUARTER |
||||||||
% Change |
||||||||
2015 |
2014 |
Reported |
Operational (1) |
Currency |
||||
CARDIOVASCULAR / METABOLISM / OTHER (5) |
||||||||
US |
1,120 |
791 |
41.6% |
41.6% |
- |
|||
Intl |
442 |
504 |
-12.3% |
-0.8% |
-11.5% |
|||
WW |
1,562 |
1,295 |
20.6% |
25.1% |
-4.5% |
|||
XARELTO |
||||||||
US |
441 |
319 |
38.2% |
38.2% |
- |
|||
Intl |
- |
- |
- |
- |
- |
|||
WW |
441 |
319 |
38.2% |
38.2% |
0.0% |
|||
INVOKANA / INVOKAMET |
||||||||
US |
266 |
93 |
* |
* |
- |
|||
Intl |
12 |
1 |
* |
* |
** |
|||
WW |
278 |
94 |
* |
* |
** |
|||
PROCRIT / EPREX |
||||||||
US |
163 |
176 |
-7.4% |
-7.4% |
- |
|||
Intl |
106 |
134 |
-20.9% |
-7.5% |
-13.4% |
|||
WW |
269 |
310 |
-13.2% |
-7.4% |
-5.8% |
|||
OTHER |
||||||||
US |
250 |
203 |
23.2% |
23.2% |
- |
|||
Intl |
324 |
369 |
-12.2% |
-1.7% |
-10.5% |
|||
WW |
574 |
572 |
0.3% |
7.1% |
-6.8% |
|||
TOTAL PHARMACEUTICAL |
||||||||
US |
4,371 |
3,740 |
16.9% |
16.9% |
- |
|||
Intl |
3,355 |
3,758 |
-10.7% |
3.7% |
-14.4% |
|||
WW |
$ 7,726 |
7,498 |
3.0% |
10.2% |
-7.2% |
|||
Supplemental Sales Information |
||||||||
2014 |
||||||||
Q1 |
Q2 |
Q3 |
Q4 |
Full Year |
||||
INVOKANA / INVOKAMET |
||||||||
US |
93 |
114 |
169 |
193 |
569 |
|||
Intl |
1 |
3 |
5 |
8 |
17 |
|||
WW |
94 |
117 |
174 |
201 |
586 |
|||
IMBRUVICA |
||||||||
US |
6 |
33 |
42 |
64 |
145 |
|||
Intl |
4 |
9 |
14 |
28 |
55 |
|||
WW |
10 |
42 |
56 |
92 |
200 |
|||
See footnotes at end of schedule |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||
FIRST QUARTER |
||||||||
% Change |
||||||||
2015 |
2014 |
Reported |
Operational (1) |
Currency |
||||
MEDICAL DEVICES (2) |
||||||||
CARDIOVASCULAR |
||||||||
US |
$ 228 |
205 |
11.2% |
11.2% |
- |
|||
Intl |
301 |
336 |
-10.4% |
3.4% |
-13.8% |
|||
WW |
529 |
541 |
-2.2% |
6.4% |
-8.6% |
|||
DIABETES |
||||||||
US |
212 |
192 |
10.4% |
10.4% |
- |
|||
Intl |
272 |
320 |
-15.0% |
0.6% |
-15.6% |
|||
WW |
484 |
512 |
-5.5% |
4.2% |
-9.7% |
|||
DIAGNOSTICS (6) |
||||||||
US |
- |
224 |
** |
** |
- |
|||
Intl |
30 |
219 |
-86.3% |
-83.5% |
-2.8% |
|||
WW |
30 |
443 |
-93.2% |
-91.8% |
-1.4% |
|||
ORTHOPAEDICS |
||||||||
US |
1,309 |
1,292 |
1.3% |
1.3% |
- |
|||
Intl |
1,019 |
1,129 |
-9.7% |
2.9% |
-12.6% |
|||
WW |
2,328 |
2,421 |
-3.8% |
2.1% |
-5.9% |
|||
SPECIALTY SURGERY / OTHER |
||||||||
US |
417 |
417 |
0.0% |
0.0% |
- |
|||
Intl |
416 |
457 |
-9.0% |
3.5% |
-12.5% |
|||
WW |
833 |
874 |
-4.7% |
1.8% |
-6.5% |
|||
SURGICAL CARE |
||||||||
US |
543 |
539 |
0.7% |
0.7% |
- |
|||
Intl |
880 |
969 |
-9.2% |
3.0% |
-12.2% |
|||
WW |
1,423 |
1,508 |
-5.6% |
2.3% |
-7.9% |
|||
VISION |
||||||||
US |
253 |
286 |
-11.5% |
-11.5% |
- |
|||
Intl |
378 |
475 |
-20.4% |
-7.5% |
-12.9% |
|||
WW |
631 |
761 |
-17.1% |
-9.0% |
-8.1% |
|||
TOTAL MEDICAL DEVICES |
||||||||
US |
2,962 |
3,155 |
-6.1% |
-6.1% |
- |
|||
Intl |
3,296 |
3,905 |
-15.6% |
-3.3% |
-12.3% |
|||
WW |
$ 6,258 |
7,060 |
-11.4% |
-4.6% |
-6.8% |
|||
* Percentage greater than 100% |
||||||||
** Not meaningful |
||||||||
(1) Operational growth excludes the effect of translational currency |
||||||||
(2) Unaudited |
||||||||
(3) Prior year amounts have been reclassified to conform to current year product disclosure |
||||||||
(4) Reported as U.S. sales |
||||||||
(5) Previously referred to as Other |
||||||||
(6) |
||||||||
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2015-first-quarter-results-300065405.html
SOURCE